United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

More than three years after launching a new corporate structure, Novartis is still making changes to its organization. | More than three years after launching a new corporate structure, Novartis is ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. | After musing a fall IPO just last week, Stada is instead being ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment ...

For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Weeks after telegraphing a series of upgrades to its Mexico operations over the next five years, Bayer is rolling up its ...

Indivior’s restructuring plan is taking shape with initial headcount reductions to help move toward a more simplified ...

Despite boasting a new owner, the Indiana manufacturing plant Novo Nordisk picked up as part of its parent company's Catalent ...